Journals / Bezmiâlem Science / 2016 / Cilt: 4 - Sayı: 3

Esmolol Administration for the Treatment of Refractory Ventricular Fibrillation

Refraktör Ventriküler Fibrilasyon Tedavisinde Esmolol Kullanımı

Pages
60–62
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, VF is still a major problem for clinicians and the treatment of refractory VF is not well defined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ventricular fibrillation (VF) after releasing an aortic cross clamp in patients undergoing open heart surgery procedures is not rare.
📊
Key Findings & Data:Ischemiareperfusion injury after release of the aortic clamp, increased adrenergic tone, and insufficient protection of the myocardium are the possible causes.
💡
Conclusion & Impact:In conclusion, VF is still a major problem for clinicians and the treatment of refractory VF is not well defined.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Ventricular fibrillation (VF) after releasing an aortic cross clamp in patients undergoing open heart surgery procedures is not rare. Ischemiareperfusion injury after release of the aortic clamp, increased adrenergic tone, and insufficient protection of the myocardium are the possible causes. Amiodarone, lidocaine, and beta blockers have been added to the cardioplegia solutions as a preventive measure for reperfusion VF. We report a case of life-threatening, shock-resistant VF during the weaning period of a cardiopulmonary bypass (CPB) in a 61-yearold male who underwent a mitral valve repair surgery for mitral valve regurgitation. After several defibrillation attempts, refractory VF was turned to normal sinus rhythm shortly after ultra-short acting, beta blocking agent esmolol administration. CPB was terminated successfully following this. In conclusion, VF is still a major problem for clinicians and the treatment of refractory VF is not well defined. In contrast with the absence of the sufficient randomized controlled human studies, theoretically beta blockers could be a choice alternative for shock refractory VF.

Özet

Açık kalp cerrahisinde aortik kros klemp kaldırılması sonrası oluşan ventriküler fibrilasyon (VF) nadir değildir. Aortik kros klemp kaldırılması sonrası oluşan iskemi-reperfüzyon hasarı, artmış adrenerjik tonus ve yetersiz miyokard koruması VF'nin olası sebepleri olarak sayılabilir. Reperfüzyon sırasında oluşan VF'den korunmak için kardiyopleji solüsyonlarına lidokaine, amiodoron ve beta bloker eklenmesi daha önce denenmiş metodlar arasındadır. Burada mitral kapak tamiri operasyonuna alınan 61 yaşındaki erkek hastada kardiyopulmoner bypass çıkımı gelişen hayatı tehdit eden refrakter şok rezistan VF vakası sunulmuştur. Birçok defibrilasyon denemesine cevap vermeyen hasta, 1 mg/kg esmolol iv uygulamasını takiben başarılı şekilde defibrile edildi ve KPB başarı ile sonlandırıldı.Sonuç olarak; ventriküler fibrilasyon klinisyenler için hala büyük bir sorun olarak devam etmekte olup refrakter VF ile ilgili etkin bir tedavi hala tanımlanamamıştır. Yeterli prospektif randomize çalışma bulunmamasına rağmen rekrakter VF tedavisinde esmolol uygulaması bir alternatif olarak düşünülebilir.

🔖

Cite This Article

KARAASLAN, K., UMUTOĞLU, T., TOPUZ, U., AY, Y. (2016). Esmolol Administration for the Treatment of Refractory Ventricular Fibrillation. Bezmiâlem Science, Cilt: 4 - Sayı: 3, 60–62. https://ajindex.com/articles/160768

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Baraka A, Kawkabani N, Dabbous A, Nawfal M, et al. Lidocaine for prevention of reperfusion ventricular fibrillation after release of aortic cross-clamping. J Cardiothorac Vasc Anesth 2000; 14: 531-3. [CrossRef] 2. Ayoub CM, Sfeir PM, Bou-Khalil P, Azar M, Haddadin AS, Harfouch D, et al. Prophylactic amiodarone versus lidocaine for prevention of reperfusion ventricular fibrillation after release of aortic cross-clamp. Eur J Anaesthesiol 2009; 26: 1056-60. [CrossRef] 3. Bourque D, Daoust R, Huard V, Charneux M. Beta-Blockers for the treatment of cardiac arrest from ventricular fibrillation? Resuscitation 2007; 75: 434-44. [CrossRef] 4. Sun J, Ding Z, Qian Y. Effect of short-acting beta blocker on the cardiac recovery after cardiopulmonary bypass. J Cardiothorac Surg 2011; 6: 99. [CrossRef] 5. Killingsworth CR, Wei CC, Dell'Italia LJ, Ardell JL, Kingsley MA, Smith WM, et al. After Prolonged Ventricular Fibrillation Short-Acting b-Adrenergic Antagonist Esmolol Given at Reperfusion Improves Survival. Circulation 2004; 109: 2469-74. [CrossRef] 6. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical storm: sympathetic blockade versus advanced cardiac life support-guided therapy. Circulation 2000; 102: 742-7. [CrossRef] 7. Driver BE, Debaty G, Plummer DW, SmitMedicine Science h SW. Use of esmolol after failure of standard cardiopulmonary resuscitation to treat patients with refractory ventricular fibrillation. Resuscitation 2014; 85: 1337-41. [CrossRef ]